FutureTech II Acquisition Corp. (FTII)
| Market Cap | 50.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.17M |
| Shares Out | 4.29M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 202 |
| Average Volume | 10 |
| Open | 11.78 |
| Previous Close | 11.78 |
| Day's Range | 11.78 - 11.78 |
| 52-Week Range | 10.52 - 12.48 |
| Beta | -0.03 |
| RSI | 81.29 |
| Earnings Date | Aug 14, 2025 |
About FutureTech II Acquisition
FutureTech II Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on business operating in the technology industry, including artificial intelligence, robotic process automation, biomedical life science, and other related technology market. FutureTech II Acquisition Corp. was founded in 2021 and is based in New Rochelle, New York. FutureTech II Acquisition ... [Read more]
Financial Performance
Financial StatementsNews
FutureTech II Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Reports on Form 10-Q and Publicly Held Shares Rule and Makes Progress Towards Regaining Compliance
New York, New York, Dec. 04, 2024 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (the “Company”) (NASDAQ: FTII), today announced that it received an expected deficiency notification letter from t...
Longevity Biomedical, Inc. and FutureTech II Acquisition Corp. Announce Business Combination to Create Nasdaq-Listed Biopharmaceutical Company Focused on Advancing New Technologies to Promote Human Health and Longevity
New York, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Longevity Biomedical, Inc. (“Longevity” or “Longevity Biomedical”), a biopharmaceutical company focused on advancing new technologies across therapeutics, ...